Infectious pathogens produce compounds called Toll ligands that activate TLRs on lymphocytes. Acute activation triggered by certain TLRs appears to "jump start" the innate immune response, characterized by the release of inflammatory cytokines and cellular expansion. In some individuals, there is a failure to control acute inflammation, resulting in postinfectious, chronic inflammation. Susceptibility to chronic inflammation is strongly associated with an individual's MHC genes. Recent clinical trials for several autoimmune diseases characterized by chronic inflammation suggest that B lymphocyte depletion therapies dampen chronic immune activation. However, currently, there is no known mechanism that accounts for the correlation among TLR activation, MHC genetics, and a pathological role for B-lymphocytes. Our hypothesis is that TLR-acti- 
Introduction
TLRs are innate pattern-detection receptors expressed on phagocytes, macrophages, lymphocytes, and other cells. TLRs can detect PAMPs, produced by bacteria, viruses, and parasites [1] . Common TLR ligands, or PAMPs, bind to and activate TLR2, TLR3, TLR4, TLR7/8, or TLR9 [2] (Table 1) . TLRs induce cellular activation and a cascade of events that result in inflammation.
Susceptibility or resistance to pathogenic infection and most post-infectious syndromes [3, 4] strongly correlates with an individual's MHC genes, which are highly variable between individuals and reflect genetic diversity within a population. In contrast, CD74 (Ii) [5] and its cleavage products (CLIP [6] ) are derived from the nonpolymorphic invariant protein, CD74, although multiple cleavage products can result from proteolysis in the endosomal/lysosomal compartments [5] .
Some pathogens associated with TLR activation can cause long-term diseases characterized by chronic immune activation, as defined by an increase in pro-inflammatory cytokines such as TNF-␣, greater numbers of white cells, and redistribution of lymphocytes between spleen and lymph node [7] . For example, recent clinical trials for several autoimmune diseases, such as Multiple Sclerosis [8] , type I diabetes [9] , Crohn's disease [10] , and Lyme disease [11] , suggest that B lymphocyte depletion therapies dampen chronic inflammation in some individuals. Interestingly, all of these diseases linked to TLR activation have also been genetically associated with immuneresponse genes, and all have inflammation as a common characteristic.
The consequence of TLR engagement on the B cell is polyclonal, TLR-dependent B cell activation in the absence of specific antigen [2] . Specific B cell antigen receptor engagement results in antigen internalization, increased lysosomal acidity associated with antigen processing, acidity-dependent inhibition of HLA-DO (H-2O in mouse) [12] , activation of HLA-DM (H-2M in mouse) [12, 13] , and HLA-DM-dependent replacement of CLIP in the groove of MHC class II molecules with antigenic peptides [14] . Specific antigen recognition by the B cell, followed by processing and presentation of the peptides to CD4
ϩ T cells, helps focus B and T cell specificities, respectively, in adaptive immune responses [15] . Thus, it appears that B cells respond as key cellular players in adaptive, specific immunity or as mediators of the innate immune response to pathogens.
Mediated via byproducts of many infectious pathogens, polyclonal B cell activation occurs in the absence of antigen receptor engagement. However, polyclonal B cell activation, analogous to antigen-specific B cell activation, results in increased levels of B cell surface MHC class II [16 -18] . Until antigenspecific activation occurs, the presence of HLA-DO in the endosomal/lysosomal compartments of B cells delays HLA-DM from replacing endogenous CLIP with peptidic antigen until the specific antigen receptor is engaged [19] . Although TLRmediated activation of macrophages and DCs has been shown to drive maturation and loss of cell surface CLIP and improved antigen processing and presentation [20] , the impact of TLR-mediated B cell activation on conventional B cell antigen processing and presentation remains unknown.
Because TLR activation of B cells does not necessarily trigger the same intracellular signals that lead to processing and presentation as antigen receptor-driven processing and presentation, we predicted that the physiological B cell response to TLR activation would result in presentation of cell surface CLIP in the groove of MHC class II molecules on B cells. We hypothesized further that if CLIP, rather than a specific antigen, is presented on the surface of the activated B cell, the consequence will be tightly regulated survival of the CLIP ϩ B cell. As CLIP is a self-antigen, survival of the CLIP ϩ B cell may be tightly controlled by peptide exchange, resulting in T cell receptor-mediated death of antigen-non-specific B cells, such that survival is restricted to antigen-specific, activated B cells. This hypothesis purports that CLIP ϩ B cells and MHC II-dependant ease of exchange of ectopic CLIP with another peptide may control the transition between acute and chronic inflammation.
Our hypothesis is that TLR activation of non-antigen primed B cells promotes activation/inflammation that can be reversed by selective B cell death of the TLR-activated B cells. We propose that tightly controlled B cell death or removal of TLRactivated B cells is not only necessary for those B cells that do not recognize antigen specifically but also preserves B cell antigen specificity. Survival is controlled by antigen specificity and antigen receptor-driven survival signals. Therefore, we feel that the conditions that determine whether the TLR-activated B cells live or die could play an important role in controlling chronic inflammation. The following experiments were designed and executed to test this hypothesis.
MATERIALS AND METHODS

Mice
C57Black6 and B6.129 mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA) and housed at the vivarium at the CU Institute of Bioenergetics and Immunology (Colorado Springs, CO, USA). Ii (CD74)-deficient mice and H-2M-deficient mice on the B6.129 syngeneic strain background were generously provided by Dr. Scott Zamvil (University of California San Francisco, CA, USA). MyD88
Ϫ/Ϫ mice were provided by Shizuo, Akira (Osaka University, Osaka, Japan).
Antibodies
The following mAb were used in these studies: 15G4, a mAb directed against mouse MHC CLIP (I-A b complex), only when CLIP is in the groove of mouse MHC class II I-A b molecules (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-mouse CD4 (GK4.5); anti-mouse CD8; anti-mouse TNF-␣; and PE-conjugated monoclonal anti-mouse B220, obtained from BD PharMingen (San Diego, CA, USA). Mouse anti-human CLIP (clone Cer-CLIP), anti-human CD19-APC, anti-human CD20-APC, and anti-HLA-DRPerCP Cy5.5 were all obtained from BD Biosciences (San Jose, CA, USA).
TLR-binding ligands
Toll ligands included Poly I:C (Sigma Chemical Co., St. Louis, MO, USA), Pam 3 Cys (Alexis, San Diego, CA, USA), imidazoquinoline resiquimod (R848, an analog of single-stranded viral RNA, also known as CLO97; Invivogen, San Diego, CA, USA) [7] , LPS (Sigma Chemical Co.), and CpG-ODN (Invivogen, Alexis).
Peptides
Peptides used in these studies include the following (listed in 
T, CD8
ϩ T, and resting B cell isolations kits were purchased from Miltenyi Biotec (Germany) and sorted on a quadromacs magnet using the LS column, per the manufacturer's instruction. In brief, murine splenocytes were put through a 40-strainer in 2 mM EDTA in PBS. The cell isolation kits use biotinylated antibody to all cell-type markers except the cell of interest and then use an antibiotin magnetic bead-conjugated antibody to negatively select for the desired cell type. In the resting B cell kit, the activation marker CD43 is used to sort against activated B cells, thereby leaving a highly purified, resting B cell population, and cell populations were stained for CD4, CD8, or B220 before and after isolation to ensure 92%ϩ purified populations on all T cells and 96%ϩ purified populations on resting B cells.
Adoptive transfer of polyclonally activated B cells
B cells were isolated and activated for 48 h, harvested, and sampled for staining to confirm the induction of CLIP expression. Ten million CpGactivated, CLIP ϩ B cells were injected i.p. Spleens were harvested at 48 h and stained as described above for intracellular production of TNF-␣ (BD PharMingen) versus cell surface staining for CD3, B220, and CLIP.
In vivo TLR stimulations
C57Bl6 and B6.129 mice were injected with CpG-ODN (25 g/mouse), with or without selected peptides ( /ml in complete medium (RPMI 1640 supplemented with 10% FBS, penicillin, streptomycin, gentamycin, pyruvate, glutamine, and 50 M 2-ME). 
Mouse cell cultures
Cell culture with human PBMCs
Blood was taken from healthy donors and diluted with PBS. Diluted blood was layered on top of Ficoll-Paque (Amersham, Piscataway, NJ, USA) and centrifuged. Buffy coat was removed and washed in PBS. PBMCs were prepared from a total of 5 normal donors to examine the effects of TLR binding on the percentage of B cells bearing ectopic CLIP and the changes in geometric MFI of the CLIP staining, resulting from TLR stimulation with CpG-ODN, LPS, Pam-3-Cys, and Poly I:C. For these experiments, the cells were cultured at ϳ1 ϫ 10 6 /ml, and each TLR-binding ligand was added at 5 g/ml for the indicated time periods. At the end of the appropriate culture period, cells were harvested and stained for cell surface CLIP using anti-human CLIP-FITC versus anti-human MHC class II HLA-DR-PE Cy5 or anti-human CLIP-FITC versus anti-human CD19-PE. Cells were analyzed using a BD FACSCalibur for the 5 samples or a Beckman Coulter FC500.
RESULTS
TLR activation causes ectopic CLIP expression on B lymphocytes
In vitro, LPS stimulation of mouse splenocytes resulted in a time-dependent increase in exogenous CLIP associated with MHC class II on B cells, as determined by staining with an anti-mouse CLIP/class II-specific antibody [21] versus antimouse B220 (Fig. 1A) . We compared the increase in percent of CLIP ϩ B cells over time with the changes in geometric MFI and observed that the relative number of CLIP molecules per cell continues to rise over time, whereas the percentage of CLIP ϩ B cells over total number of B cells increases, peaking at 48 h, followed by a decline thereafter (Fig. 1B) . This leads us to believe that MFI can be considered a measure of the relative increase in number of CLIP molecules per cell. Detection of CLIP in mouse studies, however, is limited by availability of antibody reagents to mouse CLIP; the one currently available is a mAb that recognizes CLIP only when associated with mouse MHC class II (I-A b ) and not CLIP associated with MHC class II from other alleles.
TLRs are expressed on macrophages, DCs, and lymphocytes among other cells [1] . The increase in the number of B cells bearing ectopic CLIP and the increase in the number of molecules of CLIP per cell on the B cells may be attributed to the direct consequence of LPS binding TLR4 on the mouse B cell or the indirect effect of LPS on macrophages, other white cells, or their products. To distinguish between these possibilities, we isolated resting B cells using negative selection with antibody-coated magnetic beads (MACS, Miltenyi Biotec). For these experiments, purified and isolated, resting B cells were stimulated with LPS for 48 h and stained with antibodies to B220 versus CLIP/I-A b . LPS stimulation induced an approximately 8-fold increase in the number of CLIP ϩ B cells from purified, CLIP ϩ -resting B cells. This would suggest that induction of ectopic CLIP is the direct consequence of TLR engagement on the B cell (Fig. 1C) .
As the commercially obtainable antibody to mouse CLIP peptide recognizes CLIP only when associated with MHC class
, we are limited to seeing only a 1:1 correspondence to I-A b using this antibody. As there is an antibody to the human CLIP peptide that is not restricted to the detection of CLIP in the groove of HLA-Dr (MHC class II) molecules, but which rather recognizes CLIP independently, and as we wanted to investigate whether TLR activation would similarly induce CLIP on human B cells, we set up comparative CLIP experiments with human peripheral blood. We obtained PBMCs from 5 healthy donors, culturing the cells with no additional treatment, CpG-ODN, LPS, Pam 3 Cys, or Poly I:C, as indicated. We observed statistically significant increases in ectopic CLIP on the B cells treated with CpG-ODN and LPS (Fig. 1D) . It is important to note that our ability to detect TLR-induced CLIP on purified human B cells requires the iso- lation of PBMC from freshly drawn human blood. The use of banked blood from filtered and stored blood appears to disallow detection of ectopic B cell CLIP. To rule out the possibility that ectopic CLIP resulted solely from coincident, increased levels of nascent MHC class II on the activated B cells, we counter-stained activated B cells with an MHC class II anti-human HLA-DR, -DP, and -DQ antibody (Fig. 1E) . The increase in cell surface CLIP levels (Fig. 1D) does not correspond with the TLR-dependent changes in MHC class II (Fig. 1E) , suggesting that TLR-mediated ectopic CLIP expression is not merely the consequence of increasing levels of cell surface MHC class II. In contrast, it is interesting to note that TLR (Poly I:C, Pam 3 Cys, R848, LPS, or CpG-ODN) activation of DCs and macrophages has been shown to result in MyD88-dependent maturation, increases in MHC class II, accelerated antigen processing and presentation, and loss of cell surface CLIP. In fact, cell surface CLIP is considered an indicator of immaturity in macrophages or DCs until they are activated by TLR engagement [22] , at which point, cell surface CLIP expression decreases.
Treatment in vitro with all TLR ligands resulted in a statistically significant increase in CLIP ϩ B cells ( Fig. 2A) . As H-2M catalyzes the replacement of CLIP with peptide in lysosomes, we reasoned that ectopic CLIP on TLR-activated spleen cells from H-2M-deficient mice (H-2M Ϫ/Ϫ B6.129 background) might have higher numbers of CLIP ϩ B cells relative to strainmatched controls (Fig. 2B) . As expected in mice less able to remove endogenously loaded CLIP, we observed that the initial levels of ectopic CLIP were higher on B cells from H-2M KO (Fig. 2B) animals than on the WT counterpart (initial: Fig.  2A) . However, activation with TLR ligands CpG-ODN, R848, and Pam 3 Cys increased ectopic CLIP on H-2M-deficient B cells beyond initial levels in untreated, H-2M-deficient splenocytes. To rule out the possibility that the cell surface CLIP staining results from cross-reactivity or nonspecific binding, we performed fluorescent staining for CLIP on TLR-activated B cells from Ii-deficient animals ( Fig. 2C ) [23] . As expected, we detected little to no cell surface CLIP on B cells from the Ii-deficient animals (Fig. 2C) . As B cell-specific antigen receptor engagement results in signals that increase the acidity in the lysosomes and inhibit the activity of H-2O, subsequently allowing H-2M to catalyze the replacement of CLIP with antigenic peptide-loading into MHC class II [24] , we directly compared the effects of TLR versus antigen receptor engagement on cell surface expression of CLIP. We used anti-Ig stimulation as a known surrogate for antigen receptor signaling [25] and compared levels of ectopic CLIP and percentage of CLIP ϩ B cells with TLR-dependent B cell activation versus stimulation through the B cell antigen receptor. Splenocytes were treated in culture with anti-Ig or CpG-ODN, as indicated for 24 h, harvested, and stained for ectopic CLIP:MHC class II (Fig. 2D) . As predicted, we observed significantly less ectopic CLIP per cell by measuring geometric MFI after antigen receptor-mediated stimulation. Similarly, the percent of CLIP ϩ B cells postantigen receptor engagement was reduced significantly relative to the percentage of CLIP ϩ B cells post-TLR activation (Fig. 2D ). Anti-Ig and CpG-ODN stimulation resulted in significant and similar increases in MHC class II, as measured by changes in relative fluorescence intensity (Fig. 2E) . These results indicate that antigen receptor engagement and TLR engagement of B cells result in a similar level of activations, as measured by increases in cell surface MHC class molecules. However, TLR engagement, but not antigen receptor engagement, significantly increases the percentage of cell surface, CLIP-positive B cells and the relative amount of CLIP per cell.
To address whether TLR-induced ectopic CLIP expression on B cells is the direct result of TLR engagement and signaling, we used two experimental approaches. In the first, we used antibody to TLR3 to block TLR3 (Poly I:C)-mediated increases in CLIP expression. In the second, as TLR2, -4, -7, -8, and -9 depend on the MyD88 pathway to signal cellular activation [1] , we stimulated spleen cells from B6.129 or MyD88 KO animals on a B6.129 background with CpG (Fig. 3A) . Cells were treated with antibody to Poly I:C (eBioscience, San Diego, CA, USA) for 30 min on ice, followed by treatment with Poly I:C for 24 h. Treatment with antibody to TLR3 prevented Poly I:C-induced, ectopic CLIP expression on B cells (Fig. 3A) . CpG-ODN treatment of splenocytes from MyD88-deficient animals did not result in ectopic expression of CLIP, whereas CpG-ODN treatment of splenocytes from strain-matched B6.129 animals induced a statistically significant increase in CLIP ϩ B cells (Fig. 3B) . These results suggest that ectopic CLIP induction requires TLR engagement and signaling.
Peptide-dependent inhibition of immune activation
We reasoned that if B cells bearing ectopic CLIP were important for promoting immune activation (as defined by increased cellularity, movement from the periphery to the lymph node, and/or increased cytokine production of type I IFNs), then treatment with a competitive peptide with a higher predicted binding constant than CLIP for the peptide-binding groove in MHC class II molecules would result in decreased numbers of cells from spleen and lymph node.
As peptide and CLIP peptide affinity for MHC class II molecules is MHC allele-dependent [26] , we used the MHCPred (http://www.darrenflower.info/MHCPred/) and NetMHC (http://www.cbs.dtu.dk/services/NetMHC/) databases to determine the differences in binding affinities between CLIP for molecules encoded by mouse or the known human MHC alleles. Using newly developed software, we predicted and later synthesized peptides with sequences of 11 aa, predicted by our software to have relatively higher binding constants than CLIP for all mouse and human MHC gene products (referred to as TPP, Table 2 ).
As controls for the novel peptide, we also synthesized known and well-characterized peptides that have higher or lower affinity-binding constants for the MHC class II I-A b molecules in the B6.129 mice ( Table 2) . We injected B6.129 (H-2 b ) mice with CpG-ODN alone or CpG-ODN in combination with each of the peptides. As expected, the mice injected with CpG-ODN alone exhibited dramatic hyperplasia, as described previously [27] , in spleen (Fig. 4A, upper (Fig. 4B, lower left panel) . However, treatment with sTPP or low-affinity peptide (Table 2) showed no reduction in the percent of CPG-induced CLIP ϩ B cells, (4B, lower right panel). 
Adoptive transfer of CLIP ؉ B cells into syngeneic animals induces TNF-␣ production in the host animals
We have shown that TLR activation results in expansion of CLIP ϩ B cells. As TLRs are known to induce secretion of the pro-inflammatory cytokine TNF-␣, we sought to determine whether CLIP ϩ B cells contribute to, or are the consequence of, TLR-mediated TNF-␣ production. This experiment had 2 sequential parts. The first was to TLR-activate (using CpG-ODN, a TLR9 agonist) column-purified B cells to induce ectopic CLIP expression, confirming the induction by staining and flow cytometry analysis. For the first step in the protocol, we isolated purified, resting B cells using Miltenyi Biotec magnetic, negative selection for B cells, yielding Ͼ95% pure, resting B lymphocytes. The purified B cells were activated with CpG-ODN for 48 h and harvested, and a representative sample was stained and analyzed flow-cytometrically to confirm that the cells were CLIP ϩ .
The second part of the experimental design included injecting syngeneic mice with CpG-ODN alone (Fig. 4C) or adoptively transferring by injection the animals with the activated CLIP ϩ B cells. Fortyeight hours postinjection, splenocytes were harvested from the host animals and stained using a "cyto-perm/cyto-fix" kit with fluorochrome-conjugated antibody to TNF-␣, staining for intracellular production of TNF-␣. By comparing levels of TNF-␣ among unstimulated, CpG-ODN-activated, and adoptively transferred CLIP ϩ B cells, we detected significant increases in TNF-␣ levels with CpG-ODN injection, as expected. Injection of CLIP ϩ B cells into syngeneic animals resulted in significant increases in TNF-␣ production. The cells producing TNF-␣ were counter-stained with antibody to the TCR-CD3 complex and were determined to be a subpopulation of CD3 the production of TNF-␣ by injecting an animal directly with CpG-ODN.
Redistribution of CLIP ؉ B cells in spleen and lymph node
Following CpG-ODN injection, numbers of CLIP ϩ B cells in the spleen increased over time, peaking at 48 h (Fig. 5A) . We observed a similar, but delayed, rise in the percentage and absolute number of CLIP ϩ B cells in the lymph nodes (Fig. 5A) . This is consistent with reports of CpG-ODN-induced hyperplasia [27] . Conversely, the addition of TPP following CpG-ODN treatment caused a reduction in total cell numbers and in absolute numbers of B cells and significantly altered CLIP ϩ B cell distribution between spleen and lymph node (Fig. 5A) . We note that TPP peptide treatment reduced the expansion of splenic and lymph node CD4 ϩ T cells (Fig. 5B) , reduced CD8
ϩ T cell expansion in the lymph node (Fig. 5D ), but did not block expansion of CD8 ϩ T cells in the spleen (Fig. 5C ).
Peptide-dependent B cell death
CD4 ϩ T cells, T regulatory cells specifically, have been reported to kill polyclonally activated B cells [28] . As MHC engagement of nonantigen-primed B cells results in B cell death [29] , we reasoned that peptide exchange for CLIP on activated B cells, in the absence of antigen receptor (or other) survival signals, may promote MHC class II-dependent B cell death by interaction with CD4 ϩ T cells. To assess the possibility that exogenous loading of known peptides with high, but not low peptide-binding affinity (IC 50 ; Table 2 ), would lead to an increase in B cell death of those treated with high-affinity peptides, but not in those treated with low or scrambled peptides, we monitored the number and percentage of CLIP ϩ B220-positive cells and percent live or dead B cells after treatment with CpG-ODN, with or without peptides as indicated (Fig. 6A) . These results demonstrate that high-affinity, but not low or scrambled high-affinity, peptides lead to death of polyclonally activated B cells.
To determine whether death of the B cells requires CD4 TCR recognition of the peptide in the groove of MHC class II molecules, we obtained transgenic mice (OT-2 transgenics). These mice have been generated to express a single TCR specificity for a peptide derived from the protein OVA (Table 2) , formerly occupied by CLIP (Fig. 6B) .
Our results reveal that treatment with Toll ligands results in polyclonal B cell activation accompanied by ectopic expression of CLIP. Furthermore, we demonstrate that targeted peptide treatment results in inhibition of cytokine production, decreased cellularity, and peptide-dependent death of TLR-activated B cells.
DISCUSSION
Our work offers a novel and previously unpredicted connection as to what may cause post-infection inflammation to become chronic in some people. Our work suggests that MHC genes determine if TLR-activated B cells can be controlled properly by T cell-receptor (TCR)-dependent B cell death. This theory supports the hypothesis that treatment of lymphocytes with Toll ligands results in polyclonal B and T cell activation and ectopic, cell-surface expression of CLIP. We propose that TLR-dependent, ectopic CLIP on the surfaces of B and T cells is a primordial response to acute infections and signals potential harm to the host, thereby initiating an inflammatory response. Subsequently, antigenic specificity triggers the transition from an acute, innate re- sponse to an adaptive, specific response by supporting the survival of antigen-specific cells and MHC-dependent death of non-specific immune cells. Although intra-lysosomal CLIP exchange is well studied, our findings that TLR engagement results consistently in ectopic, class II/CLIP complexes on B cells suggest a new and distinct immunological process that when inadequately controlled, may contribute to chronic inflammation.
These results suggest a novel therapeutic approach for redirecting immune imbalances using targeted peptides. We have computationally predicted peptides that bind to an individual's MHC gene products with higher affinity than the CLIP peptide, and we have had these target peptides individually synthesized. In mouse models, treatment of polyclonally activated CLIP ϩ B cells with synthesized targeted peptides results in significant reduction in the percentages of TLR-activated cells, inhibition of TLR-mediated hyperplasia in spleen and lymph nodes in mice, death of B cells, and a reduction of TLR-dependent cytokine production (Fig. 5) .
We propose that specific antigen-receptor engagement generates a survival signal. Reciprocally, when T cells recognize MHC class II, and B cells are polyclonally activated by TLRs, the result is death of the activated B cell [30, 31] . This mechanism could serve to prevent the production of potentially dangerous autoreactive antibodies, as generally acknowledged studies would appear to corroborate [32] .
Furthermore, we propose that the transition between acute inflammation and a specific adaptive immune response is mediated by polyclonal B cell and T cell activation. Relatively nonspecific, antipathogenic responses and inflammation can quickly promote an antimicrobial response as a part of innate immunity. For example, macrophages, ␥ ␦ T cells, and NK cells have all been shown to produce defensins as antimicrobial products [33] subsequent to infection. The human antimicrobial and chemotactic peptides, such as LL-37 and ␣-defensins, are expressed by certain lymphocyte and monocyte populations [33] . Once the acute response subsides, we suggest that an adaptive, acquired, and specific immune response is facilitated by an antigenic peptide-dependent death of the polyclonally expanded cells, while leaving a focused, specific antipeptide response, thereby limiting acute inflammation and selectively supporting survival of the antigen-specific B cells.
Conversely, failure to control the initial innate response, including exchange or loss of CLIP ϩ B and T cells, may be a contributing factor to chronic immune activation and inflammation. Although the definitive role of ectopic CLIP on activated B cells has yet to be elucidated, our observations not only reflect but serve to broaden current findings that B cell depletion is an effective therapy for diseases such as Multiple Sclerosis, type I diabetes, Crohn's disease, and Lyme disease, all characterized by chronic, immune activation. We feel our hypothesis finally sheds some light on the mechanism that triggers chronic inflammation and lends further corroboration that B cell depletion is effective because of the depletion of a subset of B cells that is causally related to inflammation [34] . 
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